Dendritic cells (DCs) were initially described in 1973 by Ralph Steinman, who observed in
mouse spleen a subpopulation of cells with a striking dendritic morphology. DCs originate …

The characterization of tumorassociated antigens recognized by human T lymphocytes in a
major histocompatibility complex (MHC) restricted fashion has opened new possibilities for …

There has been a surge of interest in the use of dendritic cell (DC) vaccination as cellular
immunotherapy for numerous cancers. Despite some encouraging results, this therapeutic …

Dendritic cells (DC) are recognized as the most potent antigen-presenting cells with the
ability to stimulate naive resting T cells and to initiate primary immune responses …

The discovery that dendritic cells (DC) play a key role in regulating antitumor immunity has
prompted considerable efforts in developing DC-based cancer vaccines for use in clinical …

According to the GLOBOCAN reports, there were about 12.7 million cancer cases and 7.6
million cancer deaths in 2008, and the cancer burden continues to increase worldwide [1]. At …

Dendritic cells (DC) constitute a unique system of cells that induce, sustain and regulate
immune responses. Distributed as sentinels throughout the body, DC are poised to capture …

If one envisions dendritic cells (DCs) as nature's adjuvant, then it is easy to predict that they
would be advantageous for cancer immunotherapy. Advances in culture processes that …

Human tumors express a number of protein antigens that can be recognized by T cells, thus
providing potential targets for cancer immunotherapy. Dendritic cells (DCs) are rare …

Dendritic cells (DC) are the most potent antigen presenting cells (APC) and the only ones
capable of presenting novel antigens to naïve T-cells. Large numbers of DC can be …